We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Read MoreHide Full Article
Key Takeaways
Erasmus MC completed the first Netherlands procedures using STXS' Genesis RMN System.
Physicians highlighted Genesis' speed, precision, and safety with the STXS MAGiC catheter.
The milestone boosts STXS' credibility and supports broader adoption of its robotic innovations.
Stereotaxis (STXS - Free Report) recently announced that physicians at Erasmus University Medical Center in Rotterdam successfully performed the first procedures in the Netherlands using its Genesis Robotic Magnetic Navigation (RMN) System.
The adoption of Genesis at a leading European cardiac center underscores the growing clinical confidence in robotic solutions for treating complex arrhythmias. With tens of millions worldwide suffering from arrhythmias, the introduction of Genesis represents a significant step toward expanding access to advanced treatment. The collaboration also reflects Stereotaxis’ continued progress in strengthening clinical partnerships while broadening the reach of its robotic innovations.
Likely Trend of STXS Stock Following the News
Following the announcement, the company's shares gained 2.5% at yesterday’s market closing. Shares have rallied 26.3% in the year-to-date period against the industry’s 11.4% decline. The S&P 500 has gained 14.4% in the same time frame.
In the long run, this milestone supports STXS by showcasing Genesis at a leading European heart center, which can encourage broader adoption among hospitals worldwide. More installations mean recurring revenue from system usage and related products, while also strengthening Stereotaxis’ reputation as a trusted innovator in robotic cardiac care, positioning the company for steady growth and long-term value creation.
Meanwhile, STXS currently has a market capitalization of $255.9 million.
Image Source: Zacks Investment Research
More on the News
Erasmus University Medical Center in Rotterdam, one of Europe’s leading cardiac centers, has become the first in the Netherlands to perform procedures using Stereotaxis’ RMN System. Physicians at the hospital praised Genesis for its speed, responsiveness, and precision, especially when paired with the company’s MAGiC catheter, noting clear improvements in safety and care for complex arrhythmia patients, including children and those with congenital heart conditions.
Erasmus MC is no stranger to Stereotaxis’ technology, having already completed over 4,500 procedures using robotic magnetic navigation. With arrhythmias affecting tens of millions globally and carrying serious health risks if untreated, the successful introduction of Genesis at such a renowned institution highlights both the clinical value and commercial potential of STXS’ solutions. This strengthens the company’s credibility with physicians and hospitals worldwide, while also supporting its mission to modernize cardiac care through robotic precision.
More on the STXS’ Genesis RMN System
The Genesis RMN System represents Stereotaxis’ next-generation robotic magnetic navigation technology for cardiac electrophysiology labs. Compared to its predecessor (Niobe), Genesis uses smaller magnets that rotate along their center of mass and are mounted on flexible robotic arms, which gives physicians far more precision and responsiveness. It is significantly faster, enabling quicker procedures and potentially increased throughput. Also, the system is designed to be smaller and lighter, which improves patient accessibility during procedures, optimizes workspace in electrophysiology (EP) labs and can reduce infrastructure burden.
On the regulatory and adoption front, Genesis RMN is already cleared for use in multiple geographies, including FDA clearance in the United States, CE-mark in Europe and recent regulatory approval in China. This growing base of clinical use helps generate data and physician experience, which in turn supports further adoption. It also means more recurring revenue from usage and maintenance, as well as from compatible catheters, such as the MAGiC line. The safety, reliability, and precision improvements are key for hospitals evaluating capital investment in EP lab robotics.
STXS’s Zacks Rank & Stocks to Consider
STXS carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System
Key Takeaways
Stereotaxis (STXS - Free Report) recently announced that physicians at Erasmus University Medical Center in Rotterdam successfully performed the first procedures in the Netherlands using its Genesis Robotic Magnetic Navigation (RMN) System.
The adoption of Genesis at a leading European cardiac center underscores the growing clinical confidence in robotic solutions for treating complex arrhythmias. With tens of millions worldwide suffering from arrhythmias, the introduction of Genesis represents a significant step toward expanding access to advanced treatment. The collaboration also reflects Stereotaxis’ continued progress in strengthening clinical partnerships while broadening the reach of its robotic innovations.
Likely Trend of STXS Stock Following the News
Following the announcement, the company's shares gained 2.5% at yesterday’s market closing. Shares have rallied 26.3% in the year-to-date period against the industry’s 11.4% decline. The S&P 500 has gained 14.4% in the same time frame.
In the long run, this milestone supports STXS by showcasing Genesis at a leading European heart center, which can encourage broader adoption among hospitals worldwide. More installations mean recurring revenue from system usage and related products, while also strengthening Stereotaxis’ reputation as a trusted innovator in robotic cardiac care, positioning the company for steady growth and long-term value creation.
Meanwhile, STXS currently has a market capitalization of $255.9 million.
Image Source: Zacks Investment Research
More on the News
Erasmus University Medical Center in Rotterdam, one of Europe’s leading cardiac centers, has become the first in the Netherlands to perform procedures using Stereotaxis’ RMN System. Physicians at the hospital praised Genesis for its speed, responsiveness, and precision, especially when paired with the company’s MAGiC catheter, noting clear improvements in safety and care for complex arrhythmia patients, including children and those with congenital heart conditions.
Erasmus MC is no stranger to Stereotaxis’ technology, having already completed over 4,500 procedures using robotic magnetic navigation. With arrhythmias affecting tens of millions globally and carrying serious health risks if untreated, the successful introduction of Genesis at such a renowned institution highlights both the clinical value and commercial potential of STXS’ solutions. This strengthens the company’s credibility with physicians and hospitals worldwide, while also supporting its mission to modernize cardiac care through robotic precision.
More on the STXS’ Genesis RMN System
The Genesis RMN System represents Stereotaxis’ next-generation robotic magnetic navigation technology for cardiac electrophysiology labs. Compared to its predecessor (Niobe), Genesis uses smaller magnets that rotate along their center of mass and are mounted on flexible robotic arms, which gives physicians far more precision and responsiveness. It is significantly faster, enabling quicker procedures and potentially increased throughput. Also, the system is designed to be smaller and lighter, which improves patient accessibility during procedures, optimizes workspace in electrophysiology (EP) labs and can reduce infrastructure burden.
On the regulatory and adoption front, Genesis RMN is already cleared for use in multiple geographies, including FDA clearance in the United States, CE-mark in Europe and recent regulatory approval in China. This growing base of clinical use helps generate data and physician experience, which in turn supports further adoption. It also means more recurring revenue from usage and maintenance, as well as from compatible catheters, such as the MAGiC line. The safety, reliability, and precision improvements are key for hospitals evaluating capital investment in EP lab robotics.
STXS’s Zacks Rank & Stocks to Consider
STXS carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Envista (NVST - Free Report) .
West Pharmaceutical reported second-quarter 2025 adjusted earnings per share (EPS) of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the consensus estimate by 5.4%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Envista reported second-quarter 2025 adjusted EPS of 26 cents, which beat the Zacks Consensus Estimate by 8.3%. Revenues of $682 million surpassed the Zacks Consensus Estimate by 6.3%. It currently carries a Zacks Rank #2 (Buy).
Envista has a long-term estimated growth rate of 16.8%. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.50%.